162 related articles for article (PubMed ID: 26405023)
1. Eltrombopag in systemic lupus erythematosus with antiphospholipid syndrome: thrombotic events.
Boulon C; Vircoulon M; Constans J
Lupus; 2016 Mar; 25(3):331. PubMed ID: 26405023
[No Abstract] [Full Text] [Related]
2. Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura in systemic lupus erythematosus.
Maroun MC; Ososki R; Andersen JC; Dhar JP
Lupus; 2015 Jun; 24(7):746-50. PubMed ID: 25416695
[TBL] [Abstract][Full Text] [Related]
3. Eltrombopag for chronic immune thrombocytopenia.
Tanimoto T; Fukunaga S; Hori A; Yagasaki F; Ono S
Lancet; 2011 Jun; 377(9781):1919; author reply 1919-20. PubMed ID: 21641478
[No Abstract] [Full Text] [Related]
4. No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura.
D'Arena G; Guariglia R; Mansueto G; Martorelli MC; Pietrantuono G; Villani O; Lerose R; Musto P
Blood; 2013 Feb; 121(7):1240-2. PubMed ID: 23411736
[No Abstract] [Full Text] [Related]
5. Cytomegalovirus-associated thrombocytopenia treated with thrombopoietin receptor agonist.
Simpson JD; Matthews GV; Brighton TA; Joseph JE
Intern Med J; 2016 Sep; 46(9):1096-9. PubMed ID: 27633469
[TBL] [Abstract][Full Text] [Related]
6. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.
Bussel JB; Cheng G; Saleh MN; Psaila B; Kovaleva L; Meddeb B; Kloczko J; Hassani H; Mayer B; Stone NL; Arning M; Provan D; Jenkins JM
N Engl J Med; 2007 Nov; 357(22):2237-47. PubMed ID: 18046028
[TBL] [Abstract][Full Text] [Related]
7. Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma.
Ferretti A; Baldacci E; Miulli E; Canichella M; Di Rocco A; Pulsoni A; Martelli M; Serrao A; Chistolini A; Gabriella Mazzucconi M; Foà R; Santoro C
Br J Haematol; 2019 Sep; 186(6):e217-e219. PubMed ID: 31364154
[No Abstract] [Full Text] [Related]
8. Sudden blindness due to bilateral central retinal artery occlusion in a patient on eltrombopag.
Au WY; Ma ES; Chow PC; Kan YT
Ann Hematol; 2014 May; 93(5):881-2. PubMed ID: 24048635
[No Abstract] [Full Text] [Related]
9. Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus.
Magnano L; Enríquez H; Esteve J; Cervera R; Espinosa G
J Rheumatol; 2014 Sep; 41(9):1895-6. PubMed ID: 25179983
[No Abstract] [Full Text] [Related]
10. Bidirectional inefficacy or intolerability of thrombopoietin receptor agonists: new data and a concise review.
Depré F; Aboud N; Mayer B; Salama A
Blood Transfus; 2018 May; 16(3):307-312. PubMed ID: 28151387
[TBL] [Abstract][Full Text] [Related]
11. Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura.
Scaramucci L; Giovannini M; Niscola P; Tendas A; Perrotti A; De Fabritiis P
Blood Transfus; 2014 Oct; 12(4):605-7. PubMed ID: 25351191
[No Abstract] [Full Text] [Related]
12. Eltrombopag.
Garnock-Jones KP; Keam SJ
Drugs; 2009; 69(5):567-76. PubMed ID: 19368418
[TBL] [Abstract][Full Text] [Related]
13. Use of eltrombopag after romiplostim in primary immune thrombocytopenia.
González-Porras JR; Mingot-Castellano ME; Andrade MM; Alonso R; Caparrós I; Arratibel MC; Fernández-Fuertes F; Cortti MJ; Pascual C; Sánchez-González B; Bernat S; Fuertes-Palacio MA; Vázquez-Paganini JA; Olivera PE; Alvarez-Román MT; Jarque I; Cortés M; Martínez-Robles V; Díaz-Gálvez FJ; Calbacho M; Fernández-Miñano C; Garcia-Frade J; González-López TJ
Br J Haematol; 2015 Apr; 169(1):111-6. PubMed ID: 25521630
[TBL] [Abstract][Full Text] [Related]
14. Thrombopoietin-receptor agonist as a treatment of thrombocytopenia associated with systemic lupus erythematosus.
Moreno Martínez MJ; Gallego P; Moreno Ramos MJ
Reumatol Clin; 2016; 12(1):57. PubMed ID: 26024588
[No Abstract] [Full Text] [Related]
15. Severe immune thrombocytopenia in pregnancy treated with Eltrombopag - A case report.
Ferreira IJMCF; Sousa F; Vasco EM; Areia ALFA; Moura JPAS; Carda J; Ribeiro L
J Gynecol Obstet Hum Reprod; 2018 Oct; 47(8):405-408. PubMed ID: 29981476
[TBL] [Abstract][Full Text] [Related]
16. Initial Experience with the Use of Thrombopoetin Receptor Agonists in Patients with Refractory HIV-Associated Immune Thrombocytopenic Purpura: A Case Series.
Kowalczyk M; Rubinstein PG; Aboulafia DM
J Int Assoc Provid AIDS Care; 2015; 14(3):211-6. PubMed ID: 25504472
[TBL] [Abstract][Full Text] [Related]
17. Sustained response after discontinuation of short-and medium-term treatment with eltrombopag in patients with immune thrombocytopenia.
González-López TJ; Sánchez-González B; Pascual C; Arefi M; de Cabo E; Alonso A; Martín-Salces M; Jiménez-Bárcenas R; Calbacho M; Galan P; Barez A; González-Porras JR
Platelets; 2015; 26(1):83-6. PubMed ID: 24499036
[TBL] [Abstract][Full Text] [Related]
18. Eltrombopag for chronic immune thrombocytopenia.
Milosevic I; Slade E; Drysdale H;
Lancet; 2016 Jan; 387(10016):336. PubMed ID: 26842445
[No Abstract] [Full Text] [Related]
19. Thrombopoietin mimetics for systemic lupus erythematosus with antiphospholipid antibodies should be discussed separately.
Kanda M; Atsumi T
Lupus; 2018 Oct; 27(11):1876-1877. PubMed ID: 29958500
[No Abstract] [Full Text] [Related]
20. Eltrombopag for chronic immune thrombocytopenia - Authors' reply.
Grainger JD;
Lancet; 2016 Jan; 387(10016):336-337. PubMed ID: 26842444
[No Abstract] [Full Text] [Related]
[Next] [New Search]
